Malcolm McColl
Vorstandsvorsitzender bei Viralytics Ltd.
Aktive Positionen von Malcolm McColl
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Viralytics Ltd. | Vorstandsvorsitzender | 01.01.2013 | - |
ImmVirX Pty Ltd.
 ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Vorstandsvorsitzender | 01.01.2019 | - |
| Vorsitzender | 04.08.2021 | - | |
| Gründer | 01.01.2019 | - |
Karriereverlauf von Malcolm McColl
Ehemalige bekannte Positionen von Malcolm McColl
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Mayne Pharma, Inc.
 Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Corporate Officer/Principal | 01.01.2007 | 01.01.2010 |
| VIRALYTICS LTD. | Direktor/Vorstandsmitglied | 21.01.2013 | - |
| Vorstandsvorsitzender | 21.01.2013 | - | |
| Investor Relations Kontakt | - | - | |
| STARPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 04.01.2011 | - |
Ausbildung von Malcolm McColl
| Melbourne Business School | Masters Business Admin |
| University of Melbourne | Undergraduate Degree |
Statistik
International
| Australien | 7 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Executive Officer | 3 |
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| STARPHARMA HOLDINGS LIMITED | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Viralytics Pty Ltd.
 Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
Mayne Pharma, Inc.
Mayne Pharma, Inc. Pharmaceuticals: MajorHealth Technology Mayne Pharma, Inc. develops pharmaceutical products. Its services include pharmaceutical development, clinical trial materials, method development and validation, trace metals, stability, and microbiology services. The company was founded in 1994 and is headquartered in Greenville, NC. | Health Technology |
| Viralytics Ltd. | |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
- Börse
- Insiders
- Malcolm McColl
- Erfahrung
